Palisade Bio Inc Financials
Palisade Bio Inc (PALI) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing-built liquidity supports Palisade Bio while a development-stage cost structure continues to consume operating cash.
Cash rose from$9.8M in FY2024 to$133.4M in FY2025 even as operating cash flow remained-$10.8M , so the balance-sheet expansion did not come from operating activity. Financing cash flow supplied$134.4M in FY2025 while liabilities were only$5.0M , indicating that the enlarged cash position is primarily an equity-funded reserve rather than internally generated liquidity.
In FY2023, R&D spending was
Debt-to-equity fell from 0.5x in FY2024 to 0.0x in FY2025, shifting the capital structure away from borrowing. FY2025 liabilities were
Financial Health Signals
Palisade Bio Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Palisade Bio Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Palisade Bio Inc reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Palisade Bio Inc reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Palisade Bio Inc generated $0 in revenue in fiscal year 2025.
Palisade Bio Inc's EBITDA was -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.5% from the prior year.
Palisade Bio Inc reported -$16.8M in net income in fiscal year 2025. This represents a decrease of 16.2% from the prior year.
Cash & Balance Sheet
Palisade Bio Inc held $133.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Palisade Bio Inc's ROE was -13.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 179.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Palisade Bio Inc invested $10.2M in research and development in fiscal year 2025. This represents a decrease of 36.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
PALI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0-100.0% | $250K | $0 | N/A | $14K-12.2% | $15K-94.1% | $260K0.0% | $260K+1500.4% | $16K+56.0% | $10K-44.7% | $19K-82.9% | $110K-73.0% | $408K+4.4% | $391K |
| R&D Expenses | N/A | $10.2M-36.3% | $16.0M+132.1% | $6.9M+5.3% | $6.5M+169.4% | $2.4M+20.4% | $2.0M-50.3% | $4.1M+2.6% | $4.0M-51.1% | $8.1M-38.5% | $13.2M+4.1% | $12.6M+51.1% | $8.4M+14.8% | $7.3M+19.3% | $6.1M-17.0% | $7.4M |
| SG&A Expenses | N/A | $7.9M+35.7% | $5.8M-6.5% | $6.2M-29.2% | $8.8M-5.8% | $9.3M+50.2% | $6.2M+35.2% | $4.6M+0.6% | $4.6M-16.7% | $5.5M-27.0% | $7.5M+14.8% | $6.5M-28.2% | $9.1M+70.0% | $5.3M+1989.1% | $256K0.0% | $256K |
| Operating Income | N/A | -$18.1M-21.5% | -$14.9M-13.7% | -$13.1M+16.9% | -$15.7M+62.4% | -$41.9M-350.2% | -$9.3M-7.7% | -$8.6M-4.5% | -$8.3M+37.9% | -$13.3M+35.5% | -$20.6M-7.7% | -$19.2M-9.9% | -$17.4M-39.2% | -$12.5M-23.3% | -$10.2M+21.8% | -$13.0M |
| Interest Expense | N/A | $10K-16.7% | $12K-20.0% | $15K+15.4% | $13K-99.5% | $2.4M+920.4% | $235K+2534.5% | $9K+15.9% | $8K-95.2% | $159K-86.1% | $1.1M-37.2% | $1.8M+12.1% | $1.6M+16.2% | $1.4M+51558.9% | $3K+228.7% | $821 |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0-100.0% | $1K | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$16.8M-16.2% | -$14.4M-17.4% | -$12.3M+13.7% | -$14.3M+46.4% | -$26.6M-157.9% | -$10.3M-23.6% | -$8.4M-69.6% | -$4.9M+68.6% | -$15.7M+25.7% | -$21.1M-0.8% | -$20.9M+7.6% | -$22.6M-14.1% | -$19.8M-95.9% | -$10.1M+19.1% | -$12.5M |
| EPS (Diluted) | — | -$0.30 | -$10.19 | -$27.01 | -$16.53 | -$169.74 | -$3.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PALI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $134.3M+1134.8% | $10.9M-22.6% | $14.1M-10.9% | $15.8M+26.0% | $12.5M+314.4% | $3.0M-54.1% | $6.6M-14.3% | $7.7M-44.7% | $13.9M-38.6% | $22.6M+51.2% | $14.9M-49.9% | $29.8M+53.7% | $19.4M+121.9% | $8.8M+114.1% | $4.1M |
| Current Assets | $134.2M+1179.0% | $10.5M-21.3% | $13.3M-9.5% | $14.7M+28.0% | $11.5M+1184.2% | $896K-84.1% | $5.6M-13.2% | $6.5M-47.7% | $12.4M-40.4% | $20.9M+55.6% | $13.4M-52.3% | $28.2M+59.8% | $17.6M+130.2% | $7.7M+153.7% | $3.0M |
| Cash & Equivalents | $133.4M+1258.2% | $9.8M-21.0% | $12.4M+0.4% | $12.4M+18.0% | $10.5M+1371.9% | $713K-86.1% | $5.1M-11.6% | $5.8M-13.3% | $6.7M-56.1% | $15.2M+222.2% | $4.7M-62.3% | $12.5M-25.7% | $16.8M+126.3% | $7.4M+216.5% | $2.4M |
| Accounts Receivable | $0 | $0 | N/A | $0 | $0-100.0% | $59K+180.1% | $21K-92.8% | $294K-6.0% | $313K+2881.6% | $10K-71.9% | $37K-83.5% | $226K+2155.2% | $10K+200.0% | $3K-98.6% | $234K |
| Total Liabilities | $5.0M+46.5% | $3.4M+23.7% | $2.7M-16.6% | $3.3M-36.2% | $5.1M-73.8% | $19.6M+31.5% | $14.9M+812.3% | $1.6M-69.6% | $5.4M-52.4% | $11.3M+12.9% | $10.0M-17.7% | $12.1M+10.3% | $11.0M+518.6% | $1.8M-26.7% | $2.4M |
| Current Liabilities | $4.6M+43.3% | $3.2M+25.1% | $2.6M-14.1% | $3.0M+20.7% | $2.5M-69.1% | $8.1M+559.9% | $1.2M+16.5% | $1.1M-30.6% | $1.5M-79.3% | $7.3M+14.1% | $6.4M+60.3% | $4.0M-32.5% | $5.9M+238.0% | $1.8M-27.6% | $2.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $0-100.0% | $94K | N/A | N/A | N/A | N/A | $3.4M-58.0% | $8.1M+63.3% | $4.9M | $0 | N/A |
| Total Equity | $129.4M+1626.9% | $7.5M-33.8% | $11.3M-9.3% | $12.5M+69.4% | $7.4M+144.4% | -$16.6M-99.3% | -$8.3M-237.7% | $6.0M-29.0% | $8.5M-24.8% | $11.3M+128.1% | $5.0M-72.0% | $17.7M+110.5% | $8.4M+20.7% | $7.0M+320.1% | $1.7M |
| Retained Earnings | N/A | $135.9M+11.9% | $121.5M+11.3% | $109.2M+15.4% | $94.6M+239.1% | -$68.0M+69.4% | -$222.0M-3.9% | -$213.6M-2.4% | -$208.7M-8.1% | -$193.0M-12.3% | -$172.0M-13.8% | -$151.1M-17.6% | -$128.4M-18.3% | -$108.6M-10.3% | -$98.5M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
PALI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.2M | -$10.8M+11.0% | -$12.2M-9.5% | -$11.1M+16.7% | -$13.4M+9.6% | -$14.8M-209.8% | -$4.8M+34.3% | -$7.3M+5.7% | -$7.7M+42.7% | -$13.4M+14.1% | -$15.6M+17.5% | -$18.9M-61.7% | -$11.7M-10.5% | -$10.6M-24.9% | -$8.5M-4.7% | -$8.1M |
| Capital Expenditures | N/A | N/A | $0-100.0% | $4K-60.0% | $10K | $0-100.0% | $6K | N/A | $2K-85.0% | $11K-88.4% | $98K-44.4% | $176K-15.2% | $208K+65.8% | $125K+219.6% | $39K-80.0% | $196K |
| Free Cash Flow | N/A | N/A | -$12.2M-9.5% | -$11.1M+16.7% | -$13.4M+9.5% | -$14.8M-209.4% | -$4.8M | N/A | -$7.7M+42.7% | -$13.4M+14.6% | -$15.7M+17.8% | -$19.1M-60.4% | -$11.9M-11.2% | -$10.7M-25.8% | -$8.5M-2.7% | -$8.3M |
| Investing Cash Flow | N/A | N/A | $0+100.0% | -$4K+60.0% | -$10K+81.5% | -$54K-800.0% | -$6K | N/A | $5.0M+5414.7% | -$94K-104.0% | $2.4M | N/A | N/A | N/A | -$255K+47.0% | -$481K |
| Financing Cash Flow | $138.0M | $134.4M+1303.0% | $9.6M-14.3% | $11.2M-26.7% | $15.3M-38.0% | $24.6M+1202.1% | $1.9M-71.3% | $6.6M+263.2% | $1.8M-63.6% | $5.0M-79.0% | $23.7M | N/A | N/A | N/A | $13.8M+728.6% | $1.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PALI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -5228.0% | N/A | N/A | -68764.8% | -56071.8% | -3176.7% | -5118.1% | -127027.2% | -183896.8% | -92581.4% | -11385.4% | -2491.1% | -3325.6% |
| Net Margin | N/A | N/A | -4920.0% | N/A | N/A | -76346.1% | -54252.6% | -1894.1% | -6025.4% | -129721.8% | -200671.0% | -120154.7% | -18029.0% | -2482.5% | -3204.7% |
| Return on Equity | -13.0%+179.7pp | -192.7%-84.0pp | -108.7%+5.6pp | -114.3%+247.1pp | -361.4% | N/A | N/A | -81.4%+102.6pp | -184.0%+2.0pp | -186.0%+234.8pp | -420.8%-293.1pp | -127.7%+107.9pp | -235.6%-90.4pp | -145.2%+609.0pp | -754.2% |
| Return on Assets | -12.5%+120.2pp | -132.7%-45.2pp | -87.5%+2.9pp | -90.5%+122.3pp | -212.7%+129.2pp | -341.9%-215.1pp | -126.8%-62.8pp | -64.1%+48.7pp | -112.8%-19.6pp | -93.2%+46.6pp | -139.8%-64.0pp | -75.8%+26.3pp | -102.2%+13.5pp | -115.7%+190.7pp | -306.4% |
| Current Ratio | 28.95+25.7x | 3.24-1.9x | 5.15+0.3x | 4.89+0.3x | 4.61+4.5x | 0.11-4.5x | 4.61-1.6x | 6.19-2.0x | 8.22+5.4x | 2.85+0.8x | 2.09-4.9x | 7.03+4.1x | 2.97-1.4x | 4.36+3.1x | 1.24 |
| Debt-to-Equity | 0.04-0.4x | 0.45+0.2x | 0.240.0x | 0.26+0.3x | 0.00 | N/A | N/A | 0.27-0.4x | 0.63-0.4x | 0.99+0.3x | 0.68+0.2x | 0.45-0.1x | 0.59+0.6x | 0.00-1.5x | 1.46 |
| FCF Margin | N/A | N/A | -4454.8% | N/A | N/A | -35310.7% | N/A | -2959.3% | -5164.4% | -96726.6% | -183430.3% | -63264.4% | -9742.7% | -2089.0% | -2123.0% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Palisade Bio Inc Ranks
Frequently Asked Questions
What is Palisade Bio Inc's annual revenue?
Palisade Bio Inc (PALI) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Palisade Bio Inc profitable?
No, Palisade Bio Inc (PALI) reported a net income of -$16.8M in fiscal year 2025.
What is Palisade Bio Inc's EBITDA?
Palisade Bio Inc (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Palisade Bio Inc's return on equity (ROE)?
Palisade Bio Inc (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Palisade Bio Inc's operating cash flow?
Palisade Bio Inc (PALI) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Palisade Bio Inc's total assets?
Palisade Bio Inc (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Palisade Bio Inc spend on research and development?
Palisade Bio Inc (PALI) invested $10.2M in research and development during fiscal year 2025.
What is Palisade Bio Inc's current ratio?
Palisade Bio Inc (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.
What is Palisade Bio Inc's debt-to-equity ratio?
Palisade Bio Inc (PALI) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Palisade Bio Inc's return on assets (ROA)?
Palisade Bio Inc (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Palisade Bio Inc's cash runway?
Based on fiscal year 2025 data, Palisade Bio Inc (PALI) had $133.4M in cash against an annual operating cash burn of $10.8M. This gives an estimated cash runway of approximately 148 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Palisade Bio Inc's Piotroski F-Score?
Palisade Bio Inc (PALI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Palisade Bio Inc's earnings high quality?
Palisade Bio Inc (PALI) reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Palisade Bio Inc cover its interest payments?
Palisade Bio Inc (PALI) reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.